Kisqali 200 mg film‑coated tablets, RIBOCICLIB clinical trials

Phase I/II study to determine the safety and efficacy of Ribociclib in combination with hormone therapy and hypofractionated radiotherapy in breast cancer, with positive hormone receptors and negative HER2 status, in newly diagnosed, not immediately operable (or wishing to avoid surgery), elderly patient

This study looks at a new way to treat specific breast cancers in older women. It combines a drug called Kisqali with hormone therapy and focused radiotherapy. We want to see if this treatment is safe and effective, especially for patients who can't have or prefer to avoid surgery.